+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dactinomycin"

Dactinomycin Market Report 2025 - Product Thumbnail Image

Dactinomycin Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Dactinomycin is a chemotherapy drug used to treat ovarian cancer. It is a type of anthracycline antibiotic, which works by interfering with the growth of cancer cells. It is usually given intravenously, and is often used in combination with other drugs. Common side effects include nausea, vomiting, hair loss, and fatigue. Dactinomycin is a widely used drug for ovarian cancer, and is often used in combination with other drugs. It is generally well tolerated, and has been shown to be effective in treating the disease. It is also used in combination with other drugs to treat other types of cancer, such as breast cancer. The dactinomycin market is highly competitive, with many companies offering the drug. Some of the major players in the market include Pfizer, Merck, Bristol-Myers Squibb, and AstraZeneca. Other companies include Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more